| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $63.7M | +79.2% |
| SG&A Expense | $22.4M | +118.1% |
| Operating Income | -$86.1M | -87.9% |
| Net Income | -$81.9M | -76.6% |
| EPS (Basic) | -$1.65 | +22.5% |
| EPS (Diluted) | -$1.65 | +22.5% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $241.8M | +252.9% |
| Short-term Investments | $230.4M | +4.9% |
| Current Assets | $478.0M | +64.5% |
| Total Assets | $482.5M | +64.2% |
| Current Liabilities | $19.5M | +121.7% |
| Total Liabilities | $19.5M | +121.7% |
| Stockholders' Equity | $463.0M | +62.4% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$65.0M | -62.4% |
| Investing Cash Flow | -$10.7M | +95.2% |
| Financing Cash Flow | $248.9M | -21.8% |